Literature DB >> 19450363

Nocturnal enuresis.

Darcie Kiddoo1.   

Abstract

INTRODUCTION: Nocturnal enuresis affects 15-20% of 5-year-old children, 5% of 10 year-old-children and 1-2% of people aged 15 years and over. Without treatment, 15% of affected children will become dry each year. Nocturnal enuresis is not diagnosed in children younger than 5 years, and treatment may be inappropriate for children younger than 7 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of interventions for relief of symptoms? We searched: Medline, Embase, The Cochrane Library and other important databases up to March 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: acupuncture, anticholinergics (oxybutynin, tolterodine, hyoscyamine), desmopression, dry bed training, enuresis alarm, hypnotherapy, standard home alarm clock, tricyclics (imipramine, desipramine).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19450363      PMCID: PMC2943787     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  14 in total

1.  Prospective randomized trial using laser acupuncture versus desmopressin in the treatment of nocturnal enuresis.

Authors:  C Radmayr; A Schlager; M Studen; G Bartsch
Journal:  Eur Urol       Date:  2001-08       Impact factor: 20.096

2.  The role of urine osmolality and ions in the pathogenesis of primary enuresis nocturna and in the prediction of responses to desmopressin and conditioning therapies.

Authors:  Tolga Unüvar; Ferah Sönmez
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Nocturnal enuresis is linked to a specific gene.

Authors:  H Eiberg
Journal:  Scand J Urol Nephrol Suppl       Date:  1995

4.  Primary nocturnal enuresis: a new approach to conditioning treatment.

Authors:  F G El-Anany; H A Maghraby; S E Shaker; A M Abdel-Moneim
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

5.  Total genome scan analysis in a single extended family for primary nocturnal enuresis: evidence for a new locus (ENUR3) for primary nocturnal enuresis on chromosome 22q11.

Authors:  H Eiberg
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

6.  The genetics of primary nocturnal enuresis: inheritance and suggestion of a second major gene on chromosome 12q.

Authors:  H Arnell; K Hjälmås; M Jägervall; G Läckgren; A Stenberg; B Bengtsson; C Wassén; T Emahazion; G Annerén; U Pettersson; M Sundvall; N Dahl
Journal:  J Med Genet       Date:  1997-05       Impact factor: 6.318

Review 7.  Side effects and complications of treatment with desmopressin for enuresis.

Authors:  W L Robson; A K Leung
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

Review 8.  Comparative tolerability of drug treatment for nocturnal enuresis in children.

Authors:  Dominik Müller; Charles C Roehr; Paul Eggert
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  The influence of small functional bladder capacity and other predictors on the response to desmopressin in the management of monosymptomatic nocturnal enuresis.

Authors:  H G Rushton; A B Belman; M R Zaontz; S J Skoog; S Sihelnik
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

10.  Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q.

Authors:  H Eiberg; I Berendt; J Mohr
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

View more
  1 in total

1.  Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.

Authors:  Michel Lecendreux; Giuseppe Plazzi; Yves Dauvilliers; Carol L Rosen; Chad Ruoff; Jed Black; Rupa Parvataneni; Diane Guinta; Y Grace Wang; Emmanuel Mignot
Journal:  J Clin Sleep Med       Date:  2022-09-01       Impact factor: 4.324

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.